Pruritus News and Research

RSS

Microbial metabolites could help improve functional cure rates for hepatitis B

Chronic hepatitis B (CHB) remains a major global challenge. Current therapies suppress HBV but rarely achieve functional cure (sustained HBsAg loss).

30 Jul 2026

Review highlights traditional Chinese medicine for Chikungunya fever management

Chikungunya fever, caused by Chikungunya virus (CHIKV), has re‑emerged as a major global health threat. The 2025 outbreak in Guangdong, China – the largest local epidemic ever recorded – marks a critical epidemiological turning point.

9 Jul 2026

Stem cell infusions improve symptoms in butterfly skin disease

The intravenous infusion of mesenchymal stem cells from family donors is safe and improves symptoms such as pruritus (itching), sleep disturbances, and fatigue associated with Recessive Dystrophic Epidermolysis Bullosa (RDEB), popularly known as "butterfly skin".

18 May 2026

Study highlights critical mental health risk for eczema patients

A new international study presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2025 reveals that adults with atopic eczema (AE) are significantly more likely to experience suicidal thoughts, with researchers uncovering the key factors driving this elevated risk.

17 Sep 2025

New update to the 2023 AGS Beers Criteria highlights safer pharmacologic options for older adults

The American Geriatrics Society (AGS) has released a landmark update to its list of alternatives to medications listed in the 2023 AGS Beers Criteria - the most widely adopted guidelines to help clinicians identify potentially inappropriate medications for older adults.

18 Aug 2025

Early allergen introduction reduces childhood food allergy risk

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic treatments in managing allergic conditions.

29 May 2025

Immunotherapy replaces surgery for early-stage dMMR cancers in landmark study

Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch repair-deficient (dMMR) solid tumors across multiple types. Most patients avoided surgery with durable disease control, reshaping potential cancer treatment pathways.

28 Apr 2025

Marstacimab approved to treat patients aged 12 years and above (weighing at least 35 kg) with hemophilia A or B

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine marstacimab (Hympavzi) to prevent or reduce bleeding in patients 12 years of age and older weighing at least 35 kg with hemophilia A and B.

23 Apr 2025

Research identifies pressure-sensing protein behind gut motility

After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.

25 Mar 2025

CDC confirms black-legged ticks can cause red meat allergy in humans

Researchers confirmed that black-legged ticks (Ixodes scapularis) can trigger alpha-gal syndrome in humans. A 10-year surveillance in Maine identified 23 confirmed cases of the meat allergy outside the lone star tick’s known range.

23 Mar 2025

Ursodeoxycholic acid shows promise in treating drug-induced liver injury

Drug-induced liver injury (DILI) is a significant concern in clinical practice, arising from medications, herbs, and dietary supplements.

28 Feb 2025

Dupilumab improves symptoms of atopic dermatitis in children with co-existing conditions

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether or not they have another inflammatory condition, such as asthma, allergic rhinitis or food allergies.

5 Dec 2024

Quabodepistat combo shows promise for safer, faster tuberculosis treatment

Study highlights the safety and early bactericidal activity of quabodepistat when combined with delamanid, bedaquiline, or both, offering potential for shorter and more tolerable tuberculosis treatment regimens.

1 Dec 2024

Late-liver-stage malaria vaccine delivers 89% protection and boosts cellular immunity

Genetically attenuated malaria parasites with extended liver-stage arrest (GA2) showed 89% protection in a clinical trial, surpassing earlier vaccine candidates and highlighting the potential of cellular immunity.

26 Nov 2024

Research uncovers how parasitic worms evade itch response

Ever had an itchy nose or, worse, an unreachable spot on your back that drives you mad? Now imagine an itch that refuses to go away, no matter how hard or long you scratch.

26 Oct 2024

Ipsen's elafibranor recommended for use in patients with rare liver disease

Ipsen announced today that the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. This makes elafibranor the first medicine for PBC approved for use on the NHS in nearly a decade.

26 Oct 2024

New pipeline of drug candidates offers hope for effective MASLD treatments

Non-alcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), has become the most prevalent chronic liver disease globally.

25 Sep 2024

Review highlights mitochondrial dysfunction in cholestatic liver injury

Bile acids are essential signaling molecules derived from cholesterol metabolism in the liver and are crucial for the digestion and absorption of fats.

16 Sep 2024

Almirall's Ebglyss recommended by NICE for NHS atopic dermatitis patients

Almirall S.A., a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England.

13 Jul 2024

Study finds 41% of people with long-term itchiness have fatigue

41% of people with long-term itchiness have fatigue, likely due to persistent sleep disruption, according to new research published in the British Journal of Dermatology. In comparison, only 22% of the control group had fatigue.

15 May 2024